donate now The Fatty Liver Foundation

The NASH Education ProgramTM

Improving together the medical learning about NASH to better address its causes and consequences, and serve patients.

As a recognized leader in the NASH field, the endowment fund has a responsibility for being proactive in NASH disease awareness.

The NASH Education ProgramTM defines and drives initiatives in collaboration with an independent scientific committee² composed of four international key opinion leaders, well-known and respected in the field, with a footprint in both hepatic and metabolic diseases, and a strong presence in the United States as well as in Europe.

The objective of this public health initiative is to place the practitioner and the patient at the heart of tomorrow's awareness and education actions. It aims at producing essential and relevant scientific and medical knowledge, and at disseminating it towards targeted audiences:

  • All physician specialties, going beyond hepato-gastroenterology, i.e. including diabetologists, endocrinologists, obesity specialists, cardiologists, OB-GYN and general practitioners who will all have a key role to play in the clinical management of NASH patients;
  • Patients and their families, but also individuals at risk, who all need to understand causes, mechanisms and consequences of the disease, to fully appreciate the importance of an early diagnosis and a treatment well-suited to their condition.

Through this approach, The NASH Education ProgramTM creates opportunities to increase awareness through relevant and impactful education actions. It is obviously open to all key stakeholders in the NASH space who are committed to improving NASH patient care.

Videos from The NASH Education ProgramTM

 * NASH: A Major Public Health Issue & Growing Concern

Learn about the vital role of the liver in the body, as well as about NASH, or non-alcoholic steatohepatitis.  You will see the progression of the disease from a healthy liver to a liver with steatosis and necro-inflammation, the driving force of the disease, leading to fibrosis and ultimately to life-threatening outcomes such as cirrhosis or liver cancer – both requiring a liver transplant – or cardiovascular disease.


* Why Early Diagnosis is Important

Learn why NASH is growing as a major economical and societal issue for many countries. In fact, since it has a high prevalence and no medication currently available, healthcare systems expenses related to NASH are expected to grow globally. Early diagnosis is a major challenge in NASH management, requiring a simple, cost-effective and non-invasive solution.


* Biopsy:  The Gold Standard for Diagnosis

Learn about biopsy, the current gold standard to diagnose NASH in individuals at risk, and the most complete diagnostic solution allowing clinicians to study key characteristics of the disease. Also learn why it is not considered an ideal solution and needs complementary diagnostic tools: mainly due to its low availability, invasiveness and cost.

* What is NASH?

Stephen A. Harrison, MD, Medical Director of Pinnacle Clinical Research, San Antonio, introduces us to NAFLD (Non Alcoholic Fatty Liver Disease), and more specifically NASH (Non-alcoholic Steatohepatitis). He explains the definition of the disease, as well as its characteristics & the risks induced by its progression. He also highlights how the disease is related to the double epidemic of obesity and diabetes.

* Who is at Risk?

Mary E. Rinella, MD (Associate Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago) describes who are the patients at risk of developing NAFLD and NASH, as well as the link between NASH and cardiovascular events, the ultimate consequences of the disease, and the importance of a multidisciplinary approach to be successful in the fight against NASH.


* Improving Access to NASH Diagnosis

Arun J. Sanyal , MD (Virginia Commonwealth University Medical Center, Richmond) explains that NASH is under diagnosed because a biopsy is usually necessary to confirm diagnosis. Because NASH is a silent disease and most patients are asymptomatic until late stages of the disease, it is crucial that a new, easy-to-use, accessible non-invasive diagnostic tool becomes available soon.


* How to Resolve NASH

Kenneth Cusi, MD (Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Florida, Gainesville) explains how beneficial weight loss is for NASH patients. But most people struggle to lose weight, and more importantly keep it off. Therefore, because of the prevalence of NASH and its rapid progression, increasing awareness around NASH could help to better manage patients, but that new treatments remain a priority.

* NASH:  The Future

Vlad Ratziu, MD (Professor of Hepatology at the Pitié-Salpêtrière Hospital, Paris) explains that resolving NASH (inflammation and ballooning), the underlying cause of cirrhosis, is a recommended endpoint for clinical trials. He tells us more about the key requirements for an anti-NASH drug, especially the importance of safety and tolerability on top of efficacy.